File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Incidence, pattern and timing of brain metastases among patients with advanced breast cancer treated with trastuzumab

TitleIncidence, pattern and timing of brain metastases among patients with advanced breast cancer treated with trastuzumab
Authors
KeywordsChemicals And Cas Registry Numbers
Issue Date2006
PublisherInforma Healthcare. The Journal's web site is located at http://www.tandf.co.uk/journals/titles/0284186x.asp
Citation
Acta Oncologica, 2006, v. 45 n. 2, p. 196-201 How to Cite?
AbstractWe aim to investigate the incidence, patterns and timing of brain metastases in advanced breast cancer patients who have previously received trastuzumab. Eighty-seven patients who had received trastuzumab for advanced breast cancer from November 1999 to September 2003 at the Royal Marsden Hospital were assessed. With a median follow-up period of 11 months from commencing trastuzumab, 23 patients developed brain metastases (30% at 1 year; 95% CI 58-82%). Among 57 patients who had clinical benefits on trastuzumab, 12 (21%) patients developed first disease progression in brain with 75% of them had isolated CNS progression. Moreover, among patients who received trastuzumab as first line treatment, isolated brain metastases were the initial site of progression in 17% patients. Nearly all patients developed parenchymal brain disease. This study shows brain metastases are common phenomenon in HER2 positive advanced breast cancer patients receiving trastuzumab and also may implicate the brain as a sanctuary site for early relapse in this patient cohort. © 2006 Taylor & Francis.
Persistent Identifierhttp://hdl.handle.net/10722/132661
ISSN
2015 Impact Factor: 3.73
2015 SCImago Journal Rankings: 1.499
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorYau, Ten_HK
dc.contributor.authorSwanton, Cen_HK
dc.contributor.authorChua, Sen_HK
dc.contributor.authorSue, Aen_HK
dc.contributor.authorWalsh, Gen_HK
dc.contributor.authorRostom, Aen_HK
dc.contributor.authorJohnston, SRen_HK
dc.contributor.authorO'Brien, MERen_HK
dc.contributor.authorSmith, IEen_HK
dc.date.accessioned2011-03-28T09:27:29Z-
dc.date.available2011-03-28T09:27:29Z-
dc.date.issued2006en_HK
dc.identifier.citationActa Oncologica, 2006, v. 45 n. 2, p. 196-201en_HK
dc.identifier.issn0284-186Xen_HK
dc.identifier.urihttp://hdl.handle.net/10722/132661-
dc.description.abstractWe aim to investigate the incidence, patterns and timing of brain metastases in advanced breast cancer patients who have previously received trastuzumab. Eighty-seven patients who had received trastuzumab for advanced breast cancer from November 1999 to September 2003 at the Royal Marsden Hospital were assessed. With a median follow-up period of 11 months from commencing trastuzumab, 23 patients developed brain metastases (30% at 1 year; 95% CI 58-82%). Among 57 patients who had clinical benefits on trastuzumab, 12 (21%) patients developed first disease progression in brain with 75% of them had isolated CNS progression. Moreover, among patients who received trastuzumab as first line treatment, isolated brain metastases were the initial site of progression in 17% patients. Nearly all patients developed parenchymal brain disease. This study shows brain metastases are common phenomenon in HER2 positive advanced breast cancer patients receiving trastuzumab and also may implicate the brain as a sanctuary site for early relapse in this patient cohort. © 2006 Taylor & Francis.en_HK
dc.languageengen_US
dc.publisherInforma Healthcare. The Journal's web site is located at http://www.tandf.co.uk/journals/titles/0284186x.aspen_HK
dc.relation.ispartofActa Oncologicaen_HK
dc.subjectChemicals And Cas Registry Numbersen_US
dc.titleIncidence, pattern and timing of brain metastases among patients with advanced breast cancer treated with trastuzumaben_HK
dc.typeArticleen_HK
dc.identifier.emailYau, T: tyaucc@hku.hken_HK
dc.identifier.authorityYau, T=rp01466en_HK
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1080/02841860500486630en_HK
dc.identifier.pmid16546866-
dc.identifier.scopuseid_2-s2.0-33645104239en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-33645104239&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume45en_HK
dc.identifier.issue2en_HK
dc.identifier.spage196en_HK
dc.identifier.epage201en_HK
dc.identifier.isiWOS:000236074000011-
dc.publisher.placeUnited Kingdomen_HK
dc.identifier.scopusauthoridYau, T=23391533100en_HK
dc.identifier.scopusauthoridSwanton, C=7005912775en_HK
dc.identifier.scopusauthoridChua, S=34979909200en_HK
dc.identifier.scopusauthoridSue, A=12788418100en_HK
dc.identifier.scopusauthoridWalsh, G=7202797950en_HK
dc.identifier.scopusauthoridRostom, A=7005343902en_HK
dc.identifier.scopusauthoridJohnston, SR=35420152000en_HK
dc.identifier.scopusauthoridO'Brien, MER=7401763038en_HK
dc.identifier.scopusauthoridSmith, IE=7404426647en_HK
dc.identifier.citeulike557689-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats